Evaluation of the safety and feasibility of infra ovarian injection of menstrual blood derived stem cells (MenSCs) in women with premature ovarian failure
Phase 1
- Conditions
- premature ovarian failure.Premature menopauseE28.31
- Registration Number
- IRCT20180619040147N1
- Lead Sponsor
- Iranian academic center for education culture and research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 30
Inclusion Criteria
got married woman
normal karyotype
FSH more than 20 IU/ml
anti mullerian hormone; less than 1 ng/ml
spermogram: more than 15 million/ml, normal morphology more than 2%, sperm motility (A+B) morethan 25%anteral follicles: less than 5
Exclusion Criteria
thyroid dysfunction
immune disorders
history of cancer, chemotherapy and radiotherapy
infected by hepatitis B,C or HIV
severe endometriosis
history of ovarian surgery
diabetes
dysfunction of electrolyte or liver tests
psychological problem like depression, high stress an anxiety
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method umber and diameter of anteral follicles, FSH level, AMH level, ovary volume, menstruation. Timepoint: 3 months, 6 months and one year after cell administration. Method of measurement: sonography, embryologic evaluation, biochemical assays.
- Secondary Outcome Measures
Name Time Method